Dr. Hussein Abbas, MD, PhD

Dr. Abbas practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Abbas' NPI, 1609220532, was assigned on April 18, 2016. Dr. Abbas graduated from American University of Beirut Faculty of Medicine in 2014. Dr. Abbas' Texas license number on file is R8851.

Dr. Abbas' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Abbas' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abbas practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Abbas' primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Abbas is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Abbas' licenses on file in 10 states: Texas, Florida, Arizona, Alabama, Georgia, Mississippi, Oklahoma, Tennessee, Washington and Louisiana.

Dmand AI lists anemia, dementia, fluid and electrolyte imbalances, gastrointestinal inflammation, headaches, kidney failure, sepsis and traumatic arthropathy among the conditions Dr. Abbas treats.

CMS data shows 386 Medicare services from Dr. Abbas across 4 procedure codes in 2024, for 93 Medicare patients. Medicare paid $35,981 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 93 Medicare patients who saw Dr. Abbas in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 4.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abbas' median patient age at 68, with 54% women.

In 2024, Dr. Abbas wrote 206 Medicare Part D claims for 49 patients. 76% of them were for generic drugs. CMS names the drug for 49 of them, across 3 drugs with 11 or more claims each, at $22,863 in total drug cost. In 2023, CMS named 70 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Abbas for performance year 2024, reported as part of a group. Dr. Abbas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abbas as offering telehealth.

Dmand AI links 75 papers to Dr. Abbas, published from 2011 to 2025. 2024 was the busiest year, with 12. The most frequent topics are Leukemia, Myeloid, Acute, Lebanon and Antineoplastic Combined Chemotherapy Protocols. Dr. Abbas has published most often in Blood Adv. Dr. Abbas' most frequent co-authors are Naval Gustad Daver, MBBS, Tapan M. Kadia, MD and Gautam Borthakur, MD.

CMS Open Payments shows 5 general payments to Dr. Abbas from 5 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Novo Nordisk Inc paid the most, $117.

Dmand AI lists 9 awards for Dr. Abbas, most recently Kimberly Patterson Fellowship In Leukemia Research in 2020.

Dr. Abbas graduated from American University of Beirut Faculty of Medicine in 2014.

Dr. Abbas is in network with 14 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.